Open in Screener

ONCY

Oncolytics Biotech, Inc

Feb 20 • 04:00PM ET

0.9640

-0.0360 -3.60 %

Healthcare • Biotechnology • Canada • NASD

Feb 13, 2:01 PMCluster of C-suite insider purchases ignited 24% intraday surge.

Peers: CRSP NTLA EDIT BLUE CLLS FATE IOVA ADAP PSTX TCRT

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	2.21%	Shs Outstand	103.64M	Perf Week	15.49%
Market Cap	103.73M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	19.57%	Shs Float	98.14M	Perf Month	-17.61%
Enterprise Value	95.45M	PEG	-	EPS next Q	-0.06	Inst Own	2.72%	Short Float	3.91%	Perf Quarter	-6.41%
Income	-25.30M	P/S	-	EPS this Y	9.24%	Inst Trans	-0.43%	Short Ratio	3.24	Perf Half Y	-4.55%
Sales	0.00M	P/B	1205.00	EPS next Y	5.44%	ROA	-175.83%	Short Interest	3.83M	Perf YTD	10.30%
Book/sh	0.00	P/C	11.68	EPS next 5Y	7.08%	ROE	-745.62%	52W High	1.51 -36.16%	Perf Year	30.48%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	8.27% 23.13%	ROIC	-5238.85%	52W Low	0.33 195.89%	Perf 3Y	-42.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.32% 10.68%	Perf 5Y	-71.56%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-4.93%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-64.52%
Dividend Ex-Date	-	Quick Ratio	1.84	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.39	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	1.84	EPS Q/Q	-13.66%	SMA20	-1.20%	Beta	0.95	Target Price	5.50
Payout	-	Debt/Eq	7.50	Sales Q/Q	-	SMA50	-2.16%	Rel Volume	0.66	Prev Close	1.00
Employees	28	LT Debt/Eq	5.00	Earnings	Nov 13 BMO	SMA200	-0.72%	Avg Volume	1.18M	Price	0.96
IPO	Oct 05, 2001	Option/Short	No / Yes	EPS/Sales Surpr.	-61.39% -	Trades		Volume	783,565	Change	-3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Initiated	Lake Street	Buy	$7
Oct-06-22	Initiated	Maxim Group	Buy	$3
Feb-17-21	Initiated	H.C. Wainwright	Buy	$15

Feb-17-26 11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire) -7.79%
Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire) -7.04%
08:55AM	Oncolytics receives FDA Fast Track Designation for pelareorep (TipRanks)
Feb-04-26 08:50AM	Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer (GlobeNewswire)
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
10:19AM	Loading…
10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
Jan-15-26 04:01PM	Oncolytics Biotech Announces Results of Special Meeting of Shareholders (GlobeNewswire) -7.33%
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire)
09:00AM	Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics (GlobeNewswire)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
09:00AM	Oncolytics Biotech Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer (GlobeNewswire)
04:23AM	Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances (Insider Monkey)
Jan-10-26 09:05AM	Oncolytics outlines strategic rationale for proposal to change jurisdiction (TipRanks)
09:00AM	Loading…
Jan-09-26 09:00AM	Oncolytics Biotech Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada (GlobeNewswire)
Jan-08-26 09:00AM	Oncolytics Biotech Provides Update on Intellectual Property Strategy and Patent Filings (Business Wire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
09:00AM	Oncolytics Biotech Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen OReilly, Dr. Neil Segal, and Dr. Van Morris (Business Wire)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire) +12.68%
09:00AM	Oncolytics Biotech Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer (Business Wire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-09-25 06:00PM	Oncolytics Biotech Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada (Business Wire)
Dec-03-25 09:35AM	Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-20-25 04:05PM	Oncolytics Biotech Provides Update on Special Meeting of Shareholders (Business Wire)
Nov-19-25 12:00PM	All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy (Zacks)
09:00AM	Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer (Business Wire)
Nov-04-25 08:00AM	Oncolytics Biotech Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy (Business Wire) -11.48%
Oct-28-25 07:30AM	Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care (PR Newswire)
09:00AM	Loading…
Oct-20-25 09:00AM	Oncolytics Biotech Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada (PR Newswire)
Sep-29-25 08:30AM	Oncolytics Biotech Announces Update for Potential First-Line Pancreatic Cancer Registration Study (PR Newswire) +9.30%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
07:00AM	Oncolytics Biotech Provides Update on GOBLET Study Progress and U.S. Site Expansion (PR Newswire)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire) +20.75%
07:00AM	Oncolytics Biotech Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions (PR Newswire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire) +10.58%
09:10AM	Oncolytics Biotech Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors (PR Newswire)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire)
08:30AM	Oncolytics Biotech Announces Upcoming Investor Conferences in September (PR Newswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire) -7.81%
12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-11-25 04:55PM	Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
Aug-08-25 09:05AM	Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep (PR Newswire) -6.20%
09:00AM	Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock Exchange (PR Newswire)
Aug-05-25 08:30AM	Oncolytics Biotech Announces Upcoming Annual General Meeting and Second Quarter Financial Results (PR Newswire) +7.58%
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -6.42%
08:30AM	Oncolytics Biotech to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End (PR Newswire)
Jul-23-25 09:39AM	Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire)
09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-22-25 03:32PM	Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules (PR Newswire)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +10.62% +5.60%
08:30AM	Oncolytics Biotech Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) -7.08%
08:30AM	Oncolytics Biotech to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers (PR Newswire)
Jul-08-25 08:30AM	Oncolytics Biotech Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies (PR Newswire) +23.76%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
07:00AM	Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) +5.79%
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -6.74%
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +10.76%
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-11-25 07:00AM	Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy Programs (PR Newswire) +34.10%
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
07:00AM	Oncolytics Biotech to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities (PR Newswire)
May-15-25 03:15AM	Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-14-25 04:01PM	Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum (PR Newswire)
May-06-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire) -6.42%
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire)
Apr-24-25 07:00AM	Oncolytics Biotech to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action (PR Newswire)
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire) -5.28%
Apr-10-25 06:09PM	Oncolytics Biotech Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital (PR Newswire) +24.56%
07:00AM	Oncolytics Biotech and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers (PR Newswire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
02:03AM	Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ... (GuruFocus.com)
Mar-07-25 07:00AM	Oncolytics Biotech Reports Highlights and Financial Results for Q4 and Year-End 2024 (PR Newswire) -6.29%
Mar-05-25 09:35AM	Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.52%
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire)
Feb-19-25 10:10AM	Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire)
07:00AM	Oncolytics Biotech Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 (PR Newswire)
Feb-18-25 07:00AM	Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer (PR Newswire)
Feb-14-25 05:15PM	Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (PR Newswire)
Feb-07-25 09:24PM	Oncolytics Biotech Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence (PR Newswire)
Feb-05-25 12:00PM	Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +5.26%
07:00AM	Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium (PR Newswire)
Jan-16-25 11:17AM	German PEI approves enrolment in cohort 5 of Oncolytics pancreatic cancer trial (Clinical Trials Arena)
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire)
07:02AM	Regulatory Approval Clears Path for Oncolytics Biotech to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data (PR Newswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
09:00AM	Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +9.00%
07:00AM	Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data (PR Newswire)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) -6.36%
Dec-18-24 11:12AM	Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments (PR Newswire)
08:45AM	Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic and Anal Cancers (GlobeNewswire)

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Jared	Chief Executive Officer	Feb 12 '26	Buy	0.84	29,500	24,839	109,000	Feb 13 07:00 AM
Kelly Jared	Chief Executive Officer	Feb 11 '26	Buy	0.84	5,600	4,682	79,500	Feb 13 07:00 AM
Look Kirk	Chief Financial Officer	Feb 12 '26	Buy	0.84	12,000	10,104	287,515	Feb 13 07:00 AM
Pisano Wayne	Director	Feb 12 '26	Buy	0.84	30,000	25,338	492,414	Feb 13 07:00 AM
Heineman Thomas Charles	Chief Medical Officer	Feb 12 '26	Buy	0.83	12,132	10,033	282,818	Feb 13 07:00 AM
Brown Deborah Margaret	Director	Feb 12 '26	Buy	0.85	25,000	21,240	109,851	Feb 13 07:00 AM
Hagerman Allison	VP, Product Development	Feb 12 '26	Buy	0.83	10,000	8,298	115,059	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Feb 11 '26	Buy	0.83	60,000	49,590	526,991	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Feb 12 '26	Buy	0.85	40,000	33,864	566,991	Feb 13 07:00 AM
Aromando Andrew	Chief Business Officer	Feb 11 '26	Buy	0.86	29,600	25,418	55,100	Feb 13 07:00 AM
Andrews Patricia S	Director	Feb 12 '26	Buy	0.86	35,400	30,292	78,128	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Jan 16 '26	Buy	1.04	100,000	103,770	466,991	Jan 20 04:30 PM

Open in Screener

ALT

Altimmune Inc

Feb 20 • 04:00PM ET

4.38

-0.11 -2.45 %

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: VTI XBI IWM VXF IBB IWO FESM VTWO VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	0.73%	Shs Outstand	104.34M	Perf Week	-4.16%
Market Cap	548.51M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	3.45%	Shs Float	103.58M	Perf Month	-5.19%
Enterprise Value	353.59M	PEG	-	EPS next Q	-0.23	Inst Own	52.77%	Short Float	23.33%	Perf Quarter	-5.81%
Income	-83.92M	P/S	27425.50	EPS this Y	27.16%	Inst Trans	13.44%	Short Ratio	4.93	Perf Half Y	20.66%
Sales	0.02M	P/B	2.26	EPS next Y	-23.82%	ROA	-45.82%	Short Interest	24.16M	Perf YTD	21.33%
Book/sh	1.94	P/C	2.60	EPS next 5Y	8.87%	ROE	-52.61%	52W High	7.73 -43.34%	Perf Year	-33.94%
Cash/sh	1.68	P/FCF	-	EPS past 3/5Y	17.12% 3.48%	ROIC	-41.70%	52W Low	2.90 51.03%	Perf 3Y	-63.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-83.45% -67.83%	Gross Margin	-495.00%	Volatility	4.20% 8.89%	Perf 5Y	-80.90%
Dividend TTM	-	EV/Sales	17679.50	EPS Y/Y TTM	31.25%	Oper. Margin	-452310.00%	ATR (14)	0.34	Perf 10Y	-92.23%
Dividend Ex-Date	-	Quick Ratio	17.18	Sales Y/Y TTM	-61.54%	Profit Margin	-419575.00%	RSI (14)	41.36	Recom	1.70
Dividend Gr. 3/5Y	- -	Current Ratio	17.18	EPS Q/Q	33.85%	SMA20	-12.40%	Beta	0.12	Target Price	19.75
Payout	-	Debt/Eq	0.09	Sales Q/Q	0.00%	SMA50	-5.44%	Rel Volume	0.84	Prev Close	4.49
Employees	59	LT Debt/Eq	0.08	Earnings	Nov 06 BMO	SMA200	-3.42%	Avg Volume	4.90M	Price	4.38
IPO	Oct 06, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.82% 257.14%	Trades		Volume	4,135,375	Change	-2.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$20
Jul-10-25	Resumed	Goldman	Sell	$1
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30

Show Previous Ratings

Feb-17-26 08:44PM	Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances (Insider Monkey)
Feb-02-26 09:55AM	Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development (Insider Monkey)
Jan-29-26 05:54PM	Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.80%
01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire)
Jan-28-26 04:13PM	Altimmune (ALT) Shares Slide On $75 Million Stock Offering (Benzinga) -17.15%
09:25PM	Loading…
Jan-27-26 09:25PM	Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.19%
Jan-23-26 02:06PM	Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly (24/7 Wall St.)
09:40AM	Unusually active option classes on open January 22nd (TipRanks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Jan-05-26 07:30AM	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH (GlobeNewswire) +16.52%
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
Dec-19-25 06:30AM	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial (GlobeNewswire) -22.77%
Dec-11-25 09:55AM	Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? (Zacks)
Dec-01-25 07:30AM	Altimmune Announces CEO Transition and Succession Plan (GlobeNewswire) -6.27%
Nov-26-25 07:30AM	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
09:55AM	Loading…
Nov-25-25 09:55AM	Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know (Zacks)
Nov-11-25 08:51AM	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-08-25 06:05AM	Altimmune price target lowered to $14 from $15 at Citizens JMP (TipRanks)
Nov-07-25 08:05AM	Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-06-25 07:00AM	Altimmune Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire) +5.07%
Nov-05-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder (GlobeNewswire)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 07:30AM	Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 (GlobeNewswire)
Oct-20-25 07:30AM	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 08:45AM	Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Sep-30-25 10:52AM	Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ALT (Business Wire)
Sep-29-25 07:30AM	Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide (GlobeNewswire) -5.25%
Sep-23-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 07:30AM	Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer (GlobeNewswire)
09:00AM	Loading…
Sep-09-25 09:00AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire)
Sep-02-25 08:45AM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Aug-26-25 08:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
07:30AM	Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-25 07:30AM	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
Aug-14-25 04:34PM	Investors in Altimmune, Inc. (ALT): Protect Your Rights - Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
Aug-13-25 04:24PM	Altimmune, Inc. (ALT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
03:07AM	Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... (GuruFocus.com)
Aug-12-25 07:00AM	Altimmune Announces Second Quarter 2025 Financial Results and Business Update (GlobeNewswire) +7.10%
Aug-11-25 07:30AM	Altimmune Board of Directors Appoints Jerry Durso as Chairman (GlobeNewswire)
Aug-05-25 07:30AM	Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 (GlobeNewswire)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-09-25 07:30AM	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) (GlobeNewswire)
01:19AM	Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial (Insider Monkey)
Jun-26-25 07:00AM	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH (GlobeNewswire) -53.18%
Jun-25-25 07:12PM	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 (GlobeNewswire) +7.23%
Jun-18-25 09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
Jun-13-25 07:30AM	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
May-21-25 11:17AM	Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential (Insider Monkey)
May-19-25 07:30AM	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks)
07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-13-25 07:00AM	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital (GlobeNewswire)
07:00AM	Altimmune Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-12-25 01:01PM	Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? (Zacks) +7.51%
06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-09-25 09:55AM	How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% (Zacks)
May-08-25 07:30AM	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress (GlobeNewswire) +8.21%
May-06-25 07:30AM	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 (GlobeNewswire) -7.37%
May-01-25 07:30AM	Altimmune to Present at Upcoming EASL International Liver Congress 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Altimmune to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
04:51AM	Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
04:51AM	Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-22-25 06:44AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-19-25 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)
Mar-06-25 07:30AM	Altimmune to Host Virtual R&D Day on March 13, 2025 (GlobeNewswire)
Mar-03-25 07:30AM	Altimmune to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -9.92%
Feb-27-25 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.08%
Feb-25-25 07:30AM	Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors (GlobeNewswire)
Feb-20-25 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 (GlobeNewswire)
Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roberts M Scot	Chief Scientific Officer	Feb 02 '26	Option Exercise	0.00	7,775	0	115,153	Feb 03 04:15 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '26	Option Exercise	0.00	9,275	0	104,670	Feb 03 04:15 PM
Garg Vipin K	Director	Jan 30 '26	Option Exercise	0.00	26,775	0	429,225	Feb 02 04:15 PM
Jordt Raymond M	Chief Business Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	69,765	Jan 29 04:15 PM
Garg Vipin K	Director	Jan 27 '26	Option Exercise	0.00	41,200	0	420,348	Jan 29 04:10 PM
Roberts M Scot	Chief Scientific Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	100,143	Jan 29 04:05 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	57,770	Jan 27 07:10 AM
Garg Vipin K	Director	Jan 25 '26	Option Exercise	0.00	42,050	0	397,132	Jan 27 07:05 AM
Roberts M Scot	Chief Scientific Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	88,666	Jan 27 07:00 AM
Pisano Wayne	Director	Jan 08 '26	Buy	4.08	5,000	20,410	13,498	Jan 09 04:10 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '26	Option Exercise	0.00	9,375	0	45,645	Jan 05 04:10 PM
Jorkasky Diane	Director	Dec 29 '25	Buy	3.80	527	2,003	527	Dec 29 04:10 PM
GILL JOHN	Director	Dec 23 '25	Buy	4.10	12,500	51,250	12,500	Dec 23 04:10 PM
Durso Jerome Benedict	Director	Dec 22 '25	Buy	4.13	12,500	51,569	12,500	Dec 22 04:10 PM
WEAVER GREGORY L	Chief Financial Officer	Nov 11 '25	Option Exercise	0.00	18,750	0	28,750	Nov 12 04:07 PM
Sohn Catherine A.	Director	Mar 17 '25	Buy	5.78	1,000	5,784	1,000	Mar 18 04:15 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 13 '25	Buy	5.20	10,000	51,996	10,000	Mar 14 07:27 AM

ONCY

Oncolytics Biotech, Inc

ALT

Altimmune Inc

Upgrade your FINVIZ experience